Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).

Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A.

Breast Cancer Res Treat. 2017 Aug;164(3):571-580. doi: 10.1007/s10549-017-4273-x. Epub 2017 May 8.

PMID:
28484925
2.

The Miller-McEntire Score for Molars Provides an Evidence-based Approach to Assigning Periodontal Prognosis for Molar Teeth.

Nunn ME, Carney WG, McNally SJ.

J Evid Based Dent Pract. 2015 Jun;15(2):73-6. doi: 10.1016/j.jebdp.2015.03.009. Epub 2015 Mar 30. No abstract available.

PMID:
25987389
3.

Open revascularization procedures are more likely to influence smoking reduction than percutaneous procedures.

Rajaee S, Cherkassky L, Marcaccio EJ Jr, Carney WI Jr, Chong TT, Garcia-Toca M, Slaiby JM.

Ann Vasc Surg. 2014 May;28(4):990-8. doi: 10.1016/j.avsg.2013.05.017. Epub 2013 Oct 27.

PMID:
24556178
4.

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

Carney WP, Bernhardt D, Jasani B.

Biomark Cancer. 2013 Aug 12;5:31-9. doi: 10.4137/BIC.S12389. Review.

5.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

6.

Microfluidics and circulating tumor cells.

Dong Y, Skelley AM, Merdek KD, Sprott KM, Jiang C, Pierceall WE, Lin J, Stocum M, Carney WP, Smirnov DA.

J Mol Diagn. 2013 Mar;15(2):149-57. doi: 10.1016/j.jmoldx.2012.09.004. Epub 2012 Dec 22. Review.

7.

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J.

Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31.

8.

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.

Cancer. 2011 Feb 1;117(3):517-25. doi: 10.1002/cncr.25394. Epub 2010 Sep 22.

9.

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V.

BMC Cancer. 2010 Apr 13;10:139. doi: 10.1186/1471-2407-10-139.

10.

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.

Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mahner S.

Gynecol Oncol. 2010 May;117(2):183-8. doi: 10.1016/j.ygyno.2009.11.029. Epub 2010 Jan 6.

PMID:
20051287
11.

Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.

Ali SM, Leitzel K, Lipton A, Carney WP, Köstler WJ.

J Clin Oncol. 2009 Dec 20;27(36):e273; author reply e274-5. doi: 10.1200/JCO.2009.23.4674. Epub 2009 Nov 16. No abstract available.

PMID:
19917836
12.

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.

Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A.

Leuk Res. 2010 Mar;34(3):399-402. doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24.

PMID:
19781774
13.

Predictors of shunt during carotid endarterectomy with routine electroencephalography monitoring.

Tan TW, Garcia-Toca M, Marcaccio EJ Jr, Carney WI Jr, Machan JT, Slaiby JM.

J Vasc Surg. 2009 Jun;49(6):1374-8. doi: 10.1016/j.jvs.2009.02.206.

14.

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN.

Int J Biol Markers. 2009 Jan-Mar;24(1):1-10.

PMID:
19404916
15.

Hidden HER-2/neu-positive breast cancer: how to maximize detection.

Carney WP.

IDrugs. 2009 Apr;12(4):238-42. Review.

PMID:
19350468
16.

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A; Serum HER-2/neu Study Group.

Cancer. 2008 Sep 15;113(6):1294-301. doi: 10.1002/cncr.23689.

17.

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.

Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W.

J Clin Oncol. 2008 Jun 1;26(16):2653-8. doi: 10.1200/JCO.2007.15.4336. Epub 2008 Apr 28.

PMID:
18443351
18.

Chronic hand ischemia treated with radial artery balloon angioplasty: case report.

Namdari S, Park MJ, Weiss AP, Carney WI.

J Hand Surg Am. 2008 Apr;33(4):551-4. doi: 10.1016/j.jhsa.2007.12.021.

PMID:
18406959
19.

Palmar bypass for digital ischemia.

Namdari S, Weiss AP, Carney WI Jr.

J Hand Surg Am. 2007 Oct;32(8):1251-8.

PMID:
17923311
20.

HER-2/neu diagnostics in breast cancer.

Carney WP, Leitzel K, Ali S, Neumann R, Lipton A.

Breast Cancer Res. 2007;9(3):207.

21.

The effects of vasoactive agents on flow through saphenous vein grafts during lower-extremity peripheral vascular surgery.

Maslow AD, Bert A, Slaiby J, Carney W, Marcaccio E.

J Cardiothorac Vasc Anesth. 2007 Jun;21(3):344-50. Epub 2007 Apr 19.

PMID:
17544884
22.

On target? The challenge of integrating biomarker research in drug development. Interview with Walter Carney.

Carney W.

Biomark Med. 2007 Jun;1(1):17-21. doi: 10.2217/17520363.1.1.17.

PMID:
20477457
23.

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

Carney WP.

Expert Rev Mol Diagn. 2007 May;7(3):309-19. Review.

PMID:
17489737
24.

Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W.

Cancer. 2007 May 15;109(10):1933-9.

25.

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.

Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.

Cancer. 2006 Nov 15;107(10):2337-45.

26.

Personal accounts: my experiences as a psychiatric patient in the 1960s.

Carney WR Jr.

Psychiatr Serv. 2005 Dec;56(12):1499-500. No abstract available.

PMID:
16339611
27.

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.

Cancer. 2005 Jul 15;104(2):257-63.

28.

Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.

Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF.

Anticancer Res. 2005 Mar-Apr;25(2B):1433-40.

29.

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.

Clin Breast Cancer. 2004 Jun;5(2):105-16. Review.

PMID:
15245613
30.

Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.

Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF.

Anticancer Res. 2004 Mar-Apr;24(2C):1083-9.

31.

The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.

Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H.

Oncol Rep. 2004 Jun;11(6):1331-6.

PMID:
15138574
32.

Aortoiliac insufficiency: long-term experience with stent placement for treatment.

Murphy TP, Ariaratnam NS, Carney WI Jr, Marcaccio EJ, Slaiby JM, Soares GM, Kim HM.

Radiology. 2004 Apr;231(1):243-9. Epub 2004 Feb 19.

PMID:
15068949
33.

Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.

Clin Chem. 2003 Oct;49(10):1579-98. Review.

34.

In situ quantification of aberrant p53 in colorectal neoplasia.

Smith SJ, Neugut A, Heitjan D, Forde K, Holt P, Santella RM, Jiin-Chyuan L, Carney W, Ward L, Brandt-Rauf PW.

Biomarkers. 2003 May-Aug;8(3-4):311-32.

PMID:
12944180
35.

Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.

Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W.

J Clin Oncol. 2003 May 15;21(10):1967-72.

PMID:
12743150
36.

Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.

Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A.

Clin Chem. 2002 Aug;48(8):1314-20.

37.

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J.

J Clin Oncol. 2002 Mar 15;20(6):1467-72.

PMID:
11896093
38.

ErbB-2 protein in sera and tumors of breast cancer patients.

Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minick R, Cody HS 3rd, Nowak E, Cortese A, Simmons RM, Carney WP, Brandt-Rauf PW.

Breast Cancer Res Treat. 1998 Jun;49(3):261-70.

PMID:
9776510
39.

Molecular epidemiology of p53 protein mutations in workers exposed to vinyl chloride.

Smith SJ, Li Y, Whitley R, Marion MJ, Partilo S, Carney WP, Brandt-Rauf PW.

Am J Epidemiol. 1998 Feb 1;147(3):302-8.

PMID:
9482505
40.
41.

Bcl-2 expression and DNA fragmentation in breast carcinoma, pathologic and steroid hormone receptors correlates.

Diaz-Cano SJ, Garcia-Moliner M, Carney W, Wolfe HJ.

Diagn Mol Pathol. 1997 Aug;6(4):199-208.

PMID:
9360841
42.

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S, Hayes DF.

J Clin Oncol. 1997 Jul;15(7):2518-25.

PMID:
9215820
43.

Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

Brandt-Rauf PW, Chen JM, Marion MJ, Smith SJ, Luo JC, Carney W, Pincus MR.

J Protein Chem. 1996 May;15(4):367-75.

PMID:
8819013
44.

The molecular epidemiology of oncoproteins. Serum p53 protein in patients with asbestosis.

Hemminki K, Partanen R, Koskinen H, Smith S, Carney W, Brandt-Rauf PW.

Chest. 1996 Mar;109(3 Suppl):22S-26S. No abstract available.

PMID:
8598138
45.

ErbB-2 protein levels in healthy, asymptomatic women.

Breuer B, Smith S, Osborne MP, Simmons RM, Carney WP, Brandt-Rauf PW.

Biomarkers. 1996;1(2):141-3. doi: 10.3109/13547509609088682.

PMID:
23888925
46.

Percutaneous revascularization of complex iliac artery stenoses and occlusions with use of Wallstents: three-year experience.

Murphy TP, Webb MS, Lambiase RE, Haas RA, Dorfman GS, Carney WI Jr, Morin CJ.

J Vasc Interv Radiol. 1996 Jan-Feb;7(1):21-7.

PMID:
8773970
47.
48.

Serum oncoproteins in asbestosis patients.

Partanen R, Koskinen H, Oksa P, Hemminki K, Carney W, Smith S, Brandt-Rauf P.

Clin Chem. 1995 Dec;41(12 Pt 2):1844-7.

49.

Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay.

Schroy PC 3rd, Brown-Shimer S, Kim K, Johnson KA, Murnane MJ, Yang S, O'Brien MJ, Carney WP, Kupchik HZ.

Cancer. 1995 Jul 15;76(2):201-9.

PMID:
8625092
50.

Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.

Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S, Carney WP, Brandt-Rauf PW.

Cancer Lett. 1995 May 8;91(2):235-40.

PMID:
7767914

Supplemental Content

Loading ...
Support Center